trending Market Intelligence /marketintelligence/en/news-insights/trending/vDVc59EnysG4Z0u5JeqI4w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca's lung scarring drug gets US FDA orphan drug designation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AstraZeneca's lung scarring drug gets US FDA orphan drug designation

AstraZeneca PLC said saracatinib was granted orphan drug designation by the U.S. Food and Drug Administration for treating a lung scarring disease.

The U.S. regulator granted the designation to saracatinib for treating idiopathic pulmonary fibrosis, a progressive lung disease that results in the scarring of the lungs — leading to shortness of breath or respiratory failure. The disorder is called idiopathic because of its unknown cause, but AstraZeneca says the cause is thought to be due to an abnormal wound-healing process that causes excessive tissue buildup in the lungs.

U.K.-based AstraZeneca said saracatinib has passed phase 1 development, but phase 2 trials for the therapy have yet to begin. Preclinical trials of the drug showed that it inhibits fibroblast activity and collagen deposition, which characterize lung fibrosis.

The U.S. FDA grants orphan designation to therapies that address rare diseases or disorders that affect below 200,000 people in the U.S. About 100,000 people are affected by IPF in the U.S.